In this study, antibodies (Ab) directed against three MSP antigens; MSP119, MSP2A, and MSP2B were analyzed in blood samples obtained from 223 Sudanese patients who presented with either severe malaria (SM) or uncomplicated malaria (UM) and from 117 malaria-free donors (MF). The results showed that the prevalence of MSP Abs was associated with the clinical outcome of malaria infection, and the Ab prevalence was age-dependent (P < 0.0005). More importantly, the prevalence of MSP Abs against the test antigens was lower in SM compared to UM (P = 0.001 to 0.020), suggesting a protective role for these Abs against SM. Furthermore, the Ab responses between individual complications of SM were significantly different.
This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
This is the net price. Taxes to be calculated in checkout.
A-Elgadir TME, Theander TG, ElGhazali G, Nielsen MA, A-Elbasit IE, Adam I, Troye-Blomberg M, Elbashir MI, Giha HA (2006) Determinants of VSA antibody responsein severe Plasmodium falciparum malaria in an area of low and unstable malaria transmission. Scand J Immunol 63:232–240
Alonso PL, Sacarlal J, Aponte JJ, Leach A, Macete E, Milman J, Mandomando I, Spiessens B, Guinovart C, Espasa M, Bassat Q, Aide P, Ofori-Anyinam O, Navia MM, Corachan S, Ceuppens M, Dubois MC, Demoitie MA, Dubovsky F, Menendez C, Tornieporth N, Ballou WR, Thompson R, Cohen J (2004) Efficacy of the RTS, S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial. Lancet 364:1411–1420
al-Yaman F, Genton B, Kramer KJ, Chang SP, Hui GS, Baisor M, Alpers MP (1996) Assessment of the role of naturally acquired antibody levels to Plasmodium falciparum merozoite surface protein-1 in protecting Papua New Guinean children from malaria morbidity. Am J Trop Med Hyg 54:443–448
Blackman MJ, Heidrich HG, Donachie S, McBride JS, Holder AA (1990) A single fragment of a malaria merozoite surface protein remains on the parasite during red cell invasion and is the target of invasion-inhibiting antibodies. Exp Med 172:379–382
Blackman MJ, Scott FT, Shai S, Holder AA (1994) Antibodies inhibit the protease mediated processing of a malaria merozoite surface protein. J Exp Med 180:389–393
Cavanagh DR, Elhassan IM, Roper C, Robinson VJ, Giha H, Holder AA, Hviid L, Theander TG, Arnot DE, McBride JS (1998) A longitudinal study of type-specific antibody responses to Plasmodium falciparum merozoite surface protein-1 in an area of unstable transmission in Sudan. J Immunol 161:347–359
Chappel JA, Holder AA (1993) Monoclonal antibodies that inhibit Plasmodium falciparum invasion in vitro recognize the first growth factor-like domain of merozoite surface protein-1. Mol Biochem Parasitol 60:303–312
Cohen S, MacGregor IA, Carrington SC (1961) Gamma globulin and acquired immunity to human malaria. Nature (London) 192:733–737
Diggs CL, Ballou WR, Miller LH (1993) The major merozoite surface protein as a malaria vaccine target. Parasitol Today 9:300–302
Dodoo D, Theander TG, Kurtzhals JA, Koram K, Riley E, Akanmori BD, Nkrumah FK, Hviid L (1999) Levels of antibody to conserved parts of Plasmodium falciparum merozoite surface protein 1 in Ghanian children are not associated with protection from clinical malaria. Infect Immun 67:2131–2137
Doolan DL, Aguiar JC, Weiss WR, Sette A, Felgner P, Regis DP, Quinones-Casas P, Yates JR 3rd, Blair PL, Richie TL, Hoffman SL, Carucci DJ (2003) Utilization of genomic sequence information to develop malaria vaccines. J Exp Biol 206:3789–3802
Edozien JC, Gilles HM, Udeozo IOK (1962) Adult and cord-blood gamma-globulin and immunity to malaria in Nigerians. Lancet ii:951–955
Egan AF, Chappel JA, Burghaus PA, Morris JS, McBride JS, Holder AA, Kaslow DC, Riley EM (1995) Serum antibodies from malaria-exposed people recognize conserved epitopes formed by the two epidermal growth factor motifs of MSP119, the carboxy terminal fragment of the major merozoite surface protein of Plasmodium falciparum. Infect Immun 63:456–466
Egan AF, Morris J, Barnish G, Allen S, Greenwood BM, Kaslow DC, Holder AA, Riley EM (1996) Clinical immunity to Plasmodium falciparum malaria is associated with serum antibodies to the 19-kDa C-terminal fragment of the merozoite surface antigen, PfMSP-1. J Infect Dis 173:765–769
Giha HA, ElGhazali G, A-Elgadir TME, A-Elbasit IE, Eltahir EM, Baraka OZ, Khier MM, Adam I, Troye-Blomberg M, Theander TG, Elbashir MI (2005) Clinical pattern of severe Plasmodium falciparum malaria in Sudan in an area characterized by seasonal and unstable malaria transmission. Trans R Soc Trop Med Hyg 99:243–251
Holder AA (1988) The precursor to major merozoite surface antigens: structure and role in immunity. Prog Allergy 41:72–97
Kohler C, Tebo AE, Dubois B, Deloron P, Kremsner PG, Luty AJ, 1-95/C Study Team (2003) Temporal variations in immune responses to conserved regions of Plasmodium falciparum merozoite surface proteins related to the severity of a prior malaria episode in Gabonese children. Trans R Soc Trop Med Hyg 97:455–461
Marshall VM, Coppel RL, Martin RK, Oduola AM, Anders RF, Kemp DJ (1991) A Plasmodium falciparum MSA-2 gene apparently generated by intragenic recombination between the two allelic families. Mol Biochem Parasitol 45:349–352
McBride JS, Newbold CI, Anand R (1985) Polymorphism of a high molecular weight schizont antigen of the human malaria parasite Plasmodium falciparum. J Exp Med 161:160–180
Metzger WG, Okenu DM, Cavanagh DR, Robinson JV, Bojang KA, Weiss HA, McBride JS, Greenwood BM, Conway DJ (2003) Serum IgG3 to the Plasmodium falciparum merozoite surface protein 2 is strongly associated with a reduced prospective risk of malaria. Parasite Immunol 25:307–312
Perraut R, Marrama L, Diouf B, Sokhna C, Tall A, Nabeth P, Trape JF, Longacre S, Mercereau-Puijalon O (2005) Antibodies to the conserved C-terminal domain of the Plasmodium falciparum merozoite surface protein 1 and to the merozoite extract and their relationship with in vitro inhibitory antibodies and protection against clinical malaria in a Senegalese village. J Infect Dis 15:264–271
Riley EM, Allen SJ, Wheeler JG, Blackman MJ, Bennett S, Takacs B, Schonfeld HJ, Holder AA, Greenwood BM (1992) Naturally acquired cellular and humoral immune responses to the major merozoite surface antigen (PfMSP1) of Plasmodium falciparum are associated with reduced malaria morbidity. Parasite Immunol 14:321–337
Smith T, Beck HP, Kitua A, Mwankusye S, Felger I, Fraser-Hurt N, Irion A, Alonso P, Teuscher T, Tanner M (1999) Age dependence of the multiplicity of Plasmodium falciparum infections and of other malariological indices in an area of high endemicity. Trans R Soc Trop Med Hyg 93:15–20
Smythe JA, Coppel RL, Brown GV, Ramasamy R, Kemp DJ, Anders RF (1988) Identification of two integral membrane proteins of Plasmodium falciparum. Proc Natl Acad Sci USA 85:5195–5199
Smythe JA, Coppel RL, Day KP, Smythe JA, Coppel RL, Day KP, Martin RK, Oduola AM, Kemp DJ, Anders RF (1991) Structural diversity in the Plasmodium falciparum merozoite surface antigen 2. Proc Nat Acad Sci USA 88:1751–1755
Staalsoe T, Shulman CE, Bulmer JN, Kawuondo K, Marsh K, Hviid L (2004) Variant surface antigen-specific IgG and protection against clinical consequences of pregnancy-associated Plasmodium falciparum malaria. Lancet 363:283–289
Taylor RR, Allen SJ, Greenwood BM, Riley EM (1998) IgG3 antibodies to Plasmodium falciparum merozoite surface protein 2 (MSP2): Increasing prevalence with age and association with clinical immunity to malaria. Am J Trop Med Hyg 58:406–413
Thomas AW, Carr DA, Carter JM, Lyon JA (1990) Sequence comparison of allelic forms of the Plasmodium falciparum merozoite surface antigen MSA2. Mol Biochem Parasitol 43:211–220
WHO (2000) Severe falciparum malaria. Communicable diseases cluster. Trans R Soc Trop Med Hyg 94:1–90
WHO (2003). The global malaria situation: current tools for prevention and control. 55th World Health Assembly. Global Fund to Fight AIDS, Tuberculosis and Malaria. WHO document no. A55/INF.DOC./6. Available at: http://www.who.int/gb/EB_WHA/PDF/WHA55/ea55id6.pdf. Accessed 7 July 2003
We are thankful to the patients and their guardians and to the volunteers for the cooperation and willingness to participate in this study. Jana McBride, David Cavanagh, and Gamila Ibrahim are thanked for provision of the MSP antigens. Our sincere gratitude is extended to Dr. John Horton, for his big effort in editing and correcting this manuscript. This investigation received financial support from the UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases (TDR) and the Multilateral Initiative on Malaria in Africa (MIM), project ID A00003.
About this article
Cite this article
A-Elgadir, T.M.E., Elbashir, M.I., Berzins, K. et al. The profile of IgG-antibody response against merozoite surface proteins 1 and 2 in severe Plasmodium falciparum malaria in Eastern Sudan. Parasitol Res 102, 401–409 (2008). https://doi.org/10.1007/s00436-007-0777-3
- Severe Malaria
- Cerebral Malaria
- Uncomplicated Malaria
- Malaria Patient